



Press Release

Monday, October 10, 2011



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR CLADRIBINE INJECTION

- **Approval momentum for Oncology products continues**

October 10, 2011 Bangalore: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for Cladribine Injection 1 mg/ ML packaged in 10 mg/ 10 mL single dose vials.

According to IMS data, the US market for generic Cladribine is approximately USD 5.3 Million with only one major player.


Cladribine is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market.

The product is expected to be launched shortly.

With the approval flow gathering momentum for Oncology products, Strides is set to emerge as an important player with complete range of products in this domain.

About Cladribine:

Cladribine belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics known as antimetabolites. Cladribine is used to treat a type of blood cancer known as hairy cell leukemia.



About Agila Specialties

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Ajay Singh – 080 6784 0813 Mr. Kannan N - +91 98450 54745 (Investors)	Hiba Kunil +91 98807 26372 hiba@corvoshandwick.co.in

